Etoricoxib in Patients With Parkinsonian Disease
ConditionParkinson Disease
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age50-70
SponsorIhab Elsayed Hassan
About this trial
Neuroinflammation is considered one of the most important factors contributing critically to pathophysiology of PD . Recently, high mobility group box-1 (HMGB1) protein has been encoded as a potential inflammatory biomarker in PD. HMGB1 mediates immune response mostly through endothelial cells and macrophage activation via targeting two vital cell receptors; Toll-like receptor 4 (TLR4) and advanced glycation end products (RAGE).
Eligibility criteria
Qualifiers
Age ≥ 18 years.
Both male and female will be included.
Patients diagnosed with PD according to Unified Parkinson's Disease Rating Scale.
Disqualifiers
Breast feeding
Patients with significant liver and kidney function abnormalities.
Alcohol and / or drug abusers.
Patients with known allergy to the study medications
Trial design
Treatments tested in this trial
- L-dopa
- Etoricoxib
Treatment groups
60 Participants
are divided into 2 treatment groupsSponsors and collaborators
Ihab Elsayed Hassan
Lead sponsor
Tanta University
Sponsor institution
Source ClinicalTrials.gov